Pfizer shows steady pharmaceutical progress with oncology growth and drug protection strength, shaping healthcare dynamics ...

(Reuters) - There were no cases of severe allergic reactions to Pfizer Inc and partner BioNTech SE's COVID-19 vaccine candidate during clinical trials, a Pfizer executive said at a regulatory ...

The company has increased its payouts over the past five years despite significant challenges.

Wall Street analysts expect Pfizer (PFE) to post quarterly earnings of $0.74 per share in its upcoming report, which indicates a year-over-year decline of 19.6%. Revenues are expected to be $13.82 ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

"The public understandably has been concerned about reports of rare, severe allergic reactions to the Moderna and Pfizer-BioNTech COVID-19 vaccines," Dr. Anthony Fauci, director of the National ...

NEW YORK (Reuters) - The U.S. Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE's COVID-19 vaccine in ...

The National Institutes of Health is reportedly planning to conduct a clinical study to determine why people are having severe allergic reactions to Pfizer's COVID-19 vaccine. According to the ...

Pfizer may have launched a multifront legal battle to prevent Metsera from heading to Novo Nordisk, but, behind the scenes, the U.S. pharma has shown some willingness to rework its own deal. Last ...